马来酸曲美布汀片治疗肠易激综合征疗效的多中心临床观察  

Clinical Effect of Cerekinon in Patients with Irritable Bowel Syndrome

作　　者：穆标[1] 刘之武[1] 姚宏昌[2] 张志广[3] 曹泽伟[4] 韩玉山[5] 杨强[6] 

机构地区：[1]天津市公安医院,天津市300042 [2]天津市第一中心医院 [3]天津医科大学第二医院 [4]天津市南开医院 [5]天津市人民医院 [6]天津市中医药大学第一附属医院

出　　处：《中国全科医学》2009年第13期1215-1216,共2页Chinese General Practice

摘　　要：目的观察舒丽启能治疗肠易激综合征患者的疗效。方法将257例患者列为观察对象,对比分析治疗前后患者的症状评分,计算各种症状的改善率。结果各种症状的改善率分别为:腹痛89.34%、腹胀85.59%、腹泻93.18%、便秘81.90%。结论舒丽启能治疗肠易激综合征安全有效。Objective To investigate the curative effect of Cerekinon on the patients with irritable bowel syndrome(IBS).Methods The effects were evaluated by symptom improvement rates before and after treatment for 257 patients with IBS.Results The rates of symptom improvement were 89.34% for abdominal pain,85.59% for flatulence,93.18% for diarrhea,and 81.90% for constipation.Conclusion Cerekinon is effective and safe for the treatment of IBS.

关 键 词：舒丽启能 肠易激综合征 多中心研究 

分 类 号：R574.62[医药卫生—消化系统]